Search research articles
Contact Us
Filters
Showing results (121-130 of 281) with videos related to
Page
of 29
Sort By:
Nature Reviews. Clinical Oncology
|
January 24, 2018
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, et al.
Nature Reviews. Clinical Oncology
|
April 5, 2017
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, et al.
Cancer Letters
|
July 4, 2024
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy
Elena Richiardone, Rim Al Roumi, Fanny Lardinois, et al.
BMC Cancer
|
November 20, 2010
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Ymera Pignochino, Ivana Sarotto, Caterina Peraldo-Neia, et al.
Frontiers in Oncology
|
November 24, 2022
Case Report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
Gianluca Mauri, Giorgio Patelli, Viviana Gori, et al.
Current Opinion in Molecular Therapeutics
|
December 15, 2010
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials
Heinz Zwierzina, Alberto Bardelli, Fortunato Ciardiello, et al.
Frontiers in Oncology
|
April 14, 2023
Corrigendum: Case report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
Gianluca Mauri, Giorgio Patelli, Viviana Gori, et al.
Cell Death & Disease
|
February 9, 2023
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
Marta Falcinelli, Giulia Dell'Omo, Elena Grassi, et al.
Targeted Oncology
|
April 13, 2010
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
Andrea Sartore-Bianchi, Katia Bencardino, Federica Di Nicolantonio, et al.
Cancer Letters
|
February 3, 2025
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
Elena Richiardone, Maria Virginia Giolito, Rim Al Roumi, et al.
Page
of 29
Search research articles
Search
Showing results (121-130 of 281) with videos related to
Sort By:
Page
of 29
Nature Reviews. Clinical Oncology
|
January 24, 2018
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, et al.
Nature Reviews. Clinical Oncology
|
April 5, 2017
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Conor A Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, et al.
Cancer Letters
|
July 4, 2024
MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy
Elena Richiardone, Rim Al Roumi, Fanny Lardinois, et al.
BMC Cancer
|
November 20, 2010
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
Ymera Pignochino, Ivana Sarotto, Caterina Peraldo-Neia, et al.
Frontiers in Oncology
|
November 24, 2022
Case Report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
Gianluca Mauri, Giorgio Patelli, Viviana Gori, et al.
Current Opinion in Molecular Therapeutics
|
December 15, 2010
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials
Heinz Zwierzina, Alberto Bardelli, Fortunato Ciardiello, et al.
Frontiers in Oncology
|
April 14, 2023
Corrigendum: Case report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
Gianluca Mauri, Giorgio Patelli, Viviana Gori, et al.
Cell Death & Disease
|
February 9, 2023
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
Marta Falcinelli, Giulia Dell'Omo, Elena Grassi, et al.
Targeted Oncology
|
April 13, 2010
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
Andrea Sartore-Bianchi, Katia Bencardino, Federica Di Nicolantonio, et al.
Cancer Letters
|
February 3, 2025
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers
Elena Richiardone, Maria Virginia Giolito, Rim Al Roumi, et al.
Page
of 29